TF and neoplasm: Weekly BLI was used to monitor tumor progression and responses to TiO2-Tf-TC nanoparticles only (100 μg/100 μL), bortezomib only (1 mg/kg), 89Zr-daratumumab only (1.2 MBq/100 μL), or RaST (1.2 MBq/100 μL 89Zr-daratumumab, followed by 100 μg/100 μL TiO2-Tf-TC nanoparticles; Figure 3).